Literature DB >> 33590411

Silencing of ZFP36L2 increases sensitivity to temozolomide through G2/M cell cycle arrest and BAX mediated apoptosis in GBM cells.

Mohd Firdaus Che Mat1, Ezanee Azlina Mohamad Hanif1, Nor Azian Abdul Murad1, Kamariah Ibrahim1, Roslan Harun2, Rahman Jamal3.   

Abstract

Despite the advancements in primary brain tumour diagnoses and treatments, the mortality rate remains high, particularly in glioblastoma (GBM). Chemoresistance, predominantly in recurrent cases, results in decreased mean survival of patients with GBM. We aimed to determine the chemosensitisation and oncogenic characteristics of zinc finger protein 36-like 2 (ZFP36L2) in LN18 GBM cells via RNA interference (RNAi) delivery. We conducted a meta-analysis of microarray datasets and RNAi screening using pooled small interference RNA (siRNA) to identify the druggable genes responsive to GBM chemosensitivity. Temozolomide-resistant LN18 cells were used to evaluate the effects of gene silencing on chemosensitisation to the sub-lethal dose (1/10 of the median inhibitory concentration [IC50]) of temozolomide. ZFP36L2 protein expression was detected by western blotting. Cell viability, proliferation, cell cycle and apoptosis assays were carried out using commercial kits. A human apoptosis array kit was used to determine the apoptosis pathway underlying chemosensitisation by siRNA against ZFP36L2 (siZFP36L2). Statistical analyses were performed using one-way analysis of variance; p > 0.05 was considered significant. The meta-analysis and RNAi screening identified ZFP36L2 as a potential marker of GBM. ZFP36L2 knockdown significantly induced apoptosis (p < 0.05). Moreover, ZFP36L2 inhibition led to increased cell cycle arrest and decreased cell proliferation. Downstream analysis showed that the sub-lethal dose of temozolomide and siZFP26L2 caused major upregulation of BCL2-associated X, apoptosis regulator (BAX). ZFP36L2 has oncogenic and chemosensitive characteristics and may play an important role in gliomagenesis through cell proliferation, cell cycle arrest and apoptosis. This suggests that RNAi combined with chemotherapy treatment such as temozolomide may be a potential GBM therapeutic intervention in the future.

Entities:  

Keywords:  Chemosensitisation; Glioblastoma; RNAi screening; Temozolomide; ZFP36L2

Mesh:

Substances:

Year:  2021        PMID: 33590411     DOI: 10.1007/s11033-021-06144-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  35 in total

1.  Loss of heterozygosity on chromosome 10q in glioblastomas, and its association with other genetic alterations and survival in Indian patients.

Authors:  Aanchal Kakkar; Vaishali Suri; Prerana Jha; Arti Srivastava; Vikas Sharma; Pankaj Pathak; Mehar Chand Sharma; Manish Singh Sharma; Shashank S Kale; Kunzang Chosdol; Manoj Phalak; Chitra Sarkar
Journal:  Neurol India       Date:  2011 Mar-Apr       Impact factor: 2.117

2.  Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA.

Authors:  W S Lai; E Carballo; J R Strum; E A Kennington; R S Phillips; P J Blackshear
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

3.  Alteration of major vault protein in human glioblastoma and its relation with EGFR and PTEN status.

Authors:  L Navarro; R Gil-Benso; J Megías; L Muñoz-Hidalgo; T San-Miguel; R C Callaghan; J M González-Darder; C López-Ginés; M J Cerdá-Nicolás
Journal:  Neuroscience       Date:  2015-04-11       Impact factor: 3.590

4.  Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.

Authors:  Zhiqiang Zhang; Yunmin Wang; Jiehan Chen; Qijia Tan; Caijun Xie; Cong Li; Wengang Zhan; Mei Wang
Journal:  Cancer Chemother Pharmacol       Date:  2016-11-10       Impact factor: 3.333

5.  Overcoming temozolomide resistance in glioblastoma via dual inhibition of NAD+ biosynthesis and base excision repair.

Authors:  Eva M Goellner; Bradford Grimme; Ashley R Brown; Ying-Chih Lin; Xiao-Hong Wang; Kelsey F Sugrue; Leah Mitchell; Ram N Trivedi; Jiang-bo Tang; Robert W Sobol
Journal:  Cancer Res       Date:  2011-03-15       Impact factor: 12.701

Review 6.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

7.  Prevalence of copy-number neutral LOH in glioblastomas revealed by genomewide analysis of laser-microdissected tissues.

Authors:  Daisuke Kuga; Masahiro Mizoguchi; Yanlei Guan; Nobuhiro Hata; Koji Yoshimoto; Tadahisa Shono; Satoshi O Suzuki; Yoji Kukita; Tomoko Tahira; Shinji Nagata; Tomio Sasaki; Kenshi Hayashi
Journal:  Neuro Oncol       Date:  2008-08-12       Impact factor: 12.300

8.  Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines.

Authors:  Danielle M Carrick; Perry J Blackshear
Journal:  Arch Biochem Biophys       Date:  2007-04-26       Impact factor: 4.013

Review 9.  The role of tristetraprolin in cancer and inflammation.

Authors:  Sandhya Sanduja; Fernando F Blanco; Lisa E Young; Vimala Kaza; Dan A Dixon
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01

Review 10.  Temozolomide resistance in glioblastoma multiforme.

Authors:  Sang Y Lee
Journal:  Genes Dis       Date:  2016-05-11
View more
  2 in total

1.  CD44-Mediated Poor Prognosis in Glioma Is Associated With M2-Polarization of Tumor-Associated Macrophages and Immunosuppression.

Authors:  Yong Xiao; Kun Yang; Zhen Wang; Mengjie Zhao; Yanxiang Deng; Wei Ji; Yuanjie Zou; Chunfa Qian; Yong Liu; Hong Xiao; Hongyi Liu
Journal:  Front Surg       Date:  2022-02-03

Review 2.  Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review.

Authors:  Yagmur Esemen; Mariam Awan; Rabeeia Parwez; Arsalan Baig; Shahinur Rahman; Ilaria Masala; Sonia Franchini; Dimitrios Giakoumettis
Journal:  Int J Mol Sci       Date:  2022-02-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.